EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria

Michaela Höck, Wegene Borena, Jürgen Brunner, Karina Wechselberger, Johanna Scheiring, Elisabeth Ralser, Ulrike Pupp Peglow, Peter Wöckinger, Elisabeth D'Costa, Verena Kaiser, Klaus Kapelari, Gisa Gerold und 3 weitere

Frontiers in Public Health · 2025

DOI: 10.3389/fpubh.2025.1686581 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Public Health, 2025. Verfasst von Michaela Höck und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics II, Medical University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Patient Acceptance of Health Care, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Since summer 2024, passive immunization with nirsevimab (Beyfortus ® ) has been recommended for all infants in Austria to prevent severe respiratory syncytial virus (RSV) infection. Maternal vaccination with RSVpreF (Abrysvo ® ), which provides transplacental protection, became available in autumn 2023. The expected public health benefits of these preventive strategies depend largely on widespread acceptance; however, real-world data from Austria are unavailable.

Objective

This study aimed to assess the acceptance and impact of RSV immunization strategies during the 2024/2025 season in Tyrol, Austria.

Methods

A retrospective study was conducted analyzing all live births at three Tyrolean maternity wards (Innsbruck, Hall, and Schwaz) from 5 December 2024 to 15 April 2025. Immunization rates were analyzed, and RSV-related hospitalization frequency and duration were compared to pre-pandemic seasons.

Results

Of 1,156 newborns, 57% received nirsevimab and 12% were protected by maternal RSVpreF protection, resulting in an overall coverage of almost 70%. RSV-related hospitalizations for infants under 1 year of age significantly decreased from 151 in pre-pandemic seasons to 47 in the post-nirsevimab season ( p = 0.018). During the post-nirsevimab season, the median age at hospital admission was significantly higher ( p < 0.001), and the length of stay was shorter ( p = 0.031). Importantly, none of the hospitalized infants received nirsevimab, and only one was born to a vaccinated mother.

Conclusion

Our findings highlight the positive impact of both RSV immunization strategies—nirsevimab and RSVpreF vaccine—while underscoring the need to enhance public awareness and education to improve immunization rates. Future immunization programs must be strengthened to provide better protection for the pediatric population and reduce RSV-associated morbidity in early life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesPatient Acceptance of Health CareAntibodies, Monoclonal, HumanizedHumansAustriaRetrospective StudiesFemaleInfantInfant, NewbornMalePregnancyAdultHospitalization

Stichwörter der Autor:innen

RSVRSVpreF vaccineacceptancenewbornnirsevimab

Substanzen

Respiratory Syncytial Virus VaccinesAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Pediatrics II, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Hygiene, Microbiology and Virology, Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria.

Zitieren

APA

Höck, M., Borena, W., Brunner, J., Wechselberger, K., Scheiring, J., Ralser, E., Pupp Peglow, U., Wöckinger, P., D'Costa, E., Kaiser, V., Kapelari, K., Gerold, G., Müller, T., Kiechl-Kohlendorfer, U., & Griesmaier, E. (2025). Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2025.1686581

Vancouver

Höck M, Borena W, Brunner J, Wechselberger K, Scheiring J, Ralser E, et al. Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria. Frontiers in Public Health. 2025. doi:10.3389/fpubh.2025.1686581

BibTeX
@article{Hck2025,
  author = {Höck, Michaela and Borena, Wegene and Brunner, Jürgen and Wechselberger, Karina and Scheiring, Johanna and Ralser, Elisabeth and Pupp Peglow, Ulrike and Wöckinger, Peter and D'Costa, Elisabeth and Kaiser, Verena and Kapelari, Klaus and Gerold, Gisa and Müller, Thomas and Kiechl-Kohlendorfer, Ursula and Griesmaier, Elke},
  title = {Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria},
  journal = {Frontiers in Public Health},
  year = {2025},
  doi = {10.3389/fpubh.2025.1686581}
}
Kostenlos starten →